AtaiBeckley (ATAI) Change in Accured Expenses (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Change in Accured Expenses of -$4.1 million in Q1 2026, down 194.27% quarter-over-quarter from -$1.4 million in Q1 2025, and down 194.27% on a YoY basis from $4.4 million in Q1 2025.
AtaiBeckley (ATAI) Change in Accured Expenses (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed Change in Accured Expenses across 6 years of filings, most recently posting -$3.6 million for Q3 2025.
- Change in Accured Expenses for Q3 2025 came in at -$3.6 million, down 167.62% year-over-year; the trailing twelve-month figure through Sep 2025 was -$2.1 million (up 4.54% YoY), and the FY2024 annual result was -$6.2 million, down 87.18% from the prior year.
- Change in Accured Expenses was -$4.1 million for Q1 2026 at AtaiBeckley, down from -$1.4 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of -$1.4 million in Q1 2025 to a low of -$4.1 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is -$270000.0 (2023), against an average of -$119052.6.
- Across the five-year window, Change in Accured Expenses soared 6546.73% in 2021 and slumped 404.44% in 2024, its largest moves.
- AtaiBeckley's Change in Accured Expenses stood at $2.5 million in 2021, then slumped by 248.71% to -$3.7 million in 2022, then jumped by 144.5% to $1.6 million in 2023, then slumped by 246.24% to -$2.4 million in 2024, then tumbled by 51.24% to -$3.6 million in 2025.
- The last three Change in Accured Expenses figures came in at -$3.6 million (Q3 2025), $5.7 million (Q2 2025), and -$1.7 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.11 Mn |
| Mar 31, 2026 | -4.11 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Jun 30, 2025 | 5.68 Mn |
| Jun 30, 2025 | 5.68 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | -4.29 Mn |
| Mar 31, 2024 | -4.29 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Dec 31, 2023 | 1.65 Mn |